research use only

Futibatinib (TAS-120) FGFR inhibitor

Name: Futibatinib (TAS-120)
Brand: Selleck Chemicals
SKU: S8848
Availability: InStock
Rating: 5 (16 reviews)

Cat.No.S8848

Futibatinib (TAS-120) is an irreversible fibroblast growth factor receptor (FGFR) inhibitor which inhibits all 4 subtypes of FGFR with enzyme IC50 values of 1.8 nM, 1.4 nM, 1.6 nM and 3.7 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

Chemical Structure

Molecular Weight: 418.45

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.92%

99.92

Related Targets	EGFR VEGFR PDGFR c-Met Src FLT3 HER2 c-Kit Bcr-Abl MEK BTK IGF-1R ALK Trk receptor Syk Axl CSF-1R c-RET FAK Mertk Tie-2 DYRK Tyro3 Ephrin receptor ROS1 Pyk2 RON DDR ACK Fer kinase
Related Products	Fexagratinib (AZD4547) PD173074 BLU9931 LY2874455 Zoligratinib (Debio-1347) PD-166866 SSR128129E H3B-6527 Fisogatinib (BLU-554) Derazantinib FIIN-2 Ferulic Acid ASP5878 Roblitinib (FGF401) Alofanib (RPT835) NSC12 PRN1371

Chemical Information, Storage & Stability

Molecular Weight	418.45	Formula	C₂₂H₂₂N₆O₃	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1448169-71-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC

Solubility

In vitro
Batch:

DMSO : 84 mg/mL ( (200.74 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.200mg/ml (10.04mM)	Taking the 1 mL working solution as an example, add 50 μL of 84 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (1.19mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	FGFR2 ^[1] (Cell-free assay) 1.4 nM FGFR3 ^[1] (Cell-free assay) 1.6 nM FGFR1 ^[1] (Cell-free assay) 1.8 nM FGFR4 ^[1] (Cell-free assay) 3.7 nM
In vitro	Futibatinib (TAS-120) is an irreversible fibroblast growth factor receptor (FGFR) inhibitor which inhibits all 4 subtypes of FGFR with enzyme IC50 values of 1.8 nM, 1.4 nM, 1.6 nM and 3.7 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
References	https://pubmed.ncbi.nlm.nih.gov/32973082/ https://pubmed.ncbi.nlm.nih.gov/32973082/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05827614	Recruiting	Non-small Cell Lung Cancer\|Non-Small Cell Lung Adenocarcinoma\|Non-Small Cell Squamous Lung Cancer\|Head and Neck Squamous Cell Carcinoma\|Esophageal Cancer\|Gastric Cancer\|Breast Cancer\|Bladder Cancer\|Ovarian Cancer\|Endometrial Cancer\|Liposarcoma	Boundless Bio	March 24 2023	Phase 1
NCT04965818	Terminated	Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations\|Non-Small Cell Lung Cancer\|KRAS Gene Mutation	Taiho Oncology Inc.	September 20 2021	Phase 1
NCT05036681	Recruiting	Metastatic Cancer\|Endometrium Cancer\|Endometrial Carcinoma	M.D. Anderson Cancer Center\|National Comprehensive Cancer Network	September 30 2021	Phase 2
NCT04024436	Active not recruiting	Metastatic Breast Cancer\|FGFR 1 High Amplification\|FGFR2 Amplification	Taiho Oncology Inc.	August 30 2019	Phase 2
NCT02052778	Completed	Cholangiocarcinoma\|Urothelial Cancer\|Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors\|Primary CNS Tumors\|Breast Cancer\|Gastric Cancer	Taiho Oncology Inc.	July 21 2014	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):